1. Home
  2. NCRA vs CMMB Comparison

NCRA vs CMMB Comparison

Compare NCRA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.42

Market Cap

2.6M

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.52

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
CMMB
Founded
2002
2004
Country
Taiwan
Israel
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
11.1M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
NCRA
CMMB
Price
$1.42
$1.52
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
2.2M
217.7K
Earning Date
04-15-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
$13,627,944.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$39.00
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.87
52 Week High
$2.68
$3.86

Technical Indicators

Market Signals
Indicator
NCRA
CMMB
Relative Strength Index (RSI) 67.28 42.24
Support Level $0.86 N/A
Resistance Level $1.74 $1.83
Average True Range (ATR) 0.19 0.27
MACD 0.05 -0.05
Stochastic Oscillator 50.43 1.82

Price Performance

Historical Comparison
NCRA
CMMB

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: